Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
BeiGene Ltd ( (HK:6160) ) has shared an announcement.
BeOne Medicines Ltd., a Swiss corporation, has announced positive topline results from a Phase 1/2 study of sonrotoclax, a next-generation investigational BCL2 inhibitor, for patients with relapsed or refractory mantle cell lymphoma (MCL). The study demonstrated clinically meaningful responses and a manageable safety profile, representing a significant milestone in BeOne’s hematology franchise. The company plans to submit the data to global regulatory bodies, including the U.S. FDA, for potential approval. This development could significantly impact the treatment landscape for MCL, offering new hope for patients with this aggressive disease.
The most recent analyst rating on (HK:6160) stock is a Hold with a HK$200.00 price target. To see the full list of analyst forecasts on BeiGene Ltd stock, see the HK:6160 Stock Forecast page.
More about BeiGene Ltd
Average Trading Volume: 6,448,784
Technical Sentiment Signal: Buy
Current Market Cap: HK$283.5B
For an in-depth examination of 6160 stock, go to TipRanks’ Overview page.